Speak To Advisor
1-800-786-7235
A healthy investment in healthier futures.

Cryo-Cell has been a publicly traded company since 1991. Governed by the Securities & Exchange Commission, our common stock trades under the OTC QB: symbol CCEL. We specialize in stem cell preservation for family use.
Cryo-Cell Reports Fiscal Second Quarter 2015 Financial Results

OLDSMAR, Fla. – July 16, 2015 Cryo-Cell International, Inc. (the “Company”) (OTC:QB Markets Group Symbol: CCEL), the world’s first private cord blood bank to separate and store stem cells in 1992, announced results for the second fiscal quarter ended May 31, 2015. 
 
Financial Results
 
Revenue

Consolidated revenues for the second quarter of fiscal 2015 were approximately $5.0 million compared to approximately $4.9 million for the second quarter of fiscal 2014.  The revenues for the second quarter of fiscal 2015 consisted of approximately $4.8 million in processing and storage fee revenue and approximately $169,000 in licensee and royalty income compared to approximately $4.7 million in processing and storage fee revenue and approximately $169,000 in licensee and royalty income for the second quarter of fiscal 2014.  The increase in processing and storage fee revenue is primarily attributable to a 10% increase in recurring 
more
Cord Blood Banking Leader Cryo-Cell Reports Fiscal First Quarter 2015 Financial Results

OLDSMAR, Fla., April 15, 2015 (GLOBE NEWSWIRE) -- Cryo-Cell International, Inc. (OTCQB:CCEL) (the "Company"), the world's first private cord blood bank to separate and store stem cells in 1992, announced results for the fiscal first quarter ended February 28, 2015.

Financial Results

Revenue
Consolidated revenues for the first quarter of fiscal 2015 were approximately $4.8 million compared to approximately $5.3 million for the first quarter of fiscal 2014, a 9% decrease. The revenues for the first quarter of fiscal 2015 consisted of approximately $4.7 million in processing and storage fees and approximately $169,000 in licensee income compared to approximately $4.4 million in processing and storage fees and approximately $963,000 in licensee income for the first quarter of fiscal 2014. Licensee income for the three month months ended February 28, 2014 consists of $794,000 related to royalty income from Cryo-Cell de Mexico ("Mexico") resulting from Mexico paying the remaining balance due under the amendment to the license agreement during the first quarter 2014. The remaining licensee income consists of royalty income earned on the processing and storage of cord blood stem cell specimens in geographic areas where the Company has license agreements.
more
Cryo-Cell Reports Financial Results for Fiscal 2014

OLDSMAR, Fla., March 3, 2015 (GLOBE NEWSWIRE) -- Cryo-Cell International, Inc. (OTCQB:CCEL) (the "Company"), the world's first private cord blood bank to separate and store stem cells in 1992, announced results for its fiscal year 2014.

"In spite of a very competitive environment in the cord blood banking industry, Cryo-Cell International was able to increase revenues in fiscal 2014 by 6% from fiscal 2013," said David Portnoy, Cryo-Cell's Chairman and Co-CEO. "We hope to improve upon this during fiscal 2015."

Financial Results

Revenue
Consolidated revenues for fiscal 2014 were approximately $20.1 million compared to approximately $19.0 million for fiscal 2013. The revenues for fiscal 2014 consisted of approximately $18.7 million in processing and storage fee revenue and approximately $1.5 million in licensee income, compared to approximately $17.7 million in processing and storage fee revenue and approximately $1.3 million in licensee income for fiscal 2013. Licensee income for the fiscal year ended November 30, 2014 consists of $794,000 related to Cryo-Cell de Mexico ("Mexico") which is a result of Mexico paying off the remaining balance due under the amendment during the first quarter of fiscal 2014, which will not recur in future periods. The remaining licensee income consists of $677,000 in royalty income earned on the processing and storage of cord blood stem cell specimens in India per the license agreement. Licensee income for the fiscal year ended November 30, 2013 consisted of $1.3 million in royalty income earned on the processing and storage of cord blood stem cell specimens in Mexico and India where the Company has license agreements.
more
Cryo-Cell Reports Fiscal Third Quarter 2014 Results

OLDSMAR, Fla., Oct. 15, 2014 (GLOBE NEWSWIRE) -- Cryo-Cell International, Inc. (the "Company") (OTCQB:CCEL), the world's first private cord blood bank to separate and store stem cells in 1992, announced results for the fiscal third quarter ended August 31, 2014.

Financial Results

Revenue
Consolidated revenues for the third quarter of fiscal 2014 were approximately $4.9 million compared to approximately $4.8 million for the third quarter of fiscal 2013. The revenues for the third quarter of fiscal 2014 consisted of approximately $4.8 million in processing and storage fee revenue and approximately $169,000 in licensee income, compared to approximately $4.5 million in processing and storage fee revenue and approximately $324,000 in licensee income for the third quarter of fiscal 2013. The 48% decrease in licensee income for the three months ended August 31, 2014 compared to the three months ended August 31, 2013 is the result of decreased licensee income from Cryo-Cell de Mexico ("Mexico") as Mexico paid the remaining balance due under the amendment to the license agreement during the first fiscal quarter of 2014. There will be no further licensee income recognized pursuant to that agreement. The remaining licensee income (and all of the licensee income for the three months ended August 31, 2013) consists of royalty income earned on the processing and storage of cord blood stem cell specimens in geographic areas where the Company has license agreements.
more
Cryo-Cell Reports Second Quarter 2014 Results

OLDSMAR, Fla., July 7, 2014 (GLOBE NEWSWIRE) -- Cryo-Cell International, Inc. (OTCQB:CCEL), the world's first private cord blood bank to separate and store stem cells in 1992, announced results for the second fiscal quarter ended May 31, 2014.

"We believe that the growth in the Company's processing and storage fees as well as the growth in net income second quarter fiscal 2014 versus second quarter fiscal 2013 demonstrate that the Company is headed in the right direction," stated David Portnoy, Cryo-Cell's Chairman and Co-CEO. Mr. Portnoy continued, "We will continue to invest the Company's capital resources in those areas which we believe will generate the highest returns for our shareholders."

Mark Portnoy, Cryo-Cell's Co-CEO, added, "Cryo-Cell continues to lead the way in the industry by raising our quality standards and becoming the first private-only cord blood bank in the U.S. to achieve FACT accreditation – the most stringent quality accrediting organization in the field of cellular therapies."
more
Cryo-Cell Reports Financial Results for Fiscal 2013

OLDSMAR, Fla., March 3, 2014 (GLOBE NEWSWIRE) -- Cryo-Cell International, Inc. (OTCQB:CCEL) (the "Company"), the world's first private cord blood bank to separate and store stem cells in 1992, today announced results for its fiscal year 2013.

"We believe Cryo-Cell's 2013 financial results give only a hint of the Company's improvements that have been implemented throughout the organization," stated David Portnoy, Cryo-Cell's Chairman and Co-CEO. "We look forward to fiscal year 2014 with much anticipation and believe that Cryo-Cell is very well positioned to benefit financially from its strong position in the cord blood banking industry."

Mark Portnoy, Cryo-Cell's Co-CEO, added, "We believe the increase in revenue in 2013 demonstrates traction for the new direction of the Company. In fact, the positive cash flow from operations was $822,000 in fiscal 2013. Excluding the $1.6 million cash payment related to the termination of the Company's former CEO, cash flow from operations would have been $2.4 million. We hope to see more progress during 2014."
more
Cryo-Cell Reports Third Quarter 2013 Results

OLDSMAR, Fla. – October 15, 2013 – Cryo-Cell International, Inc. (the “Company”) (OTC:QB Markets Group Symbol: CCEL), the world’s first private cord blood bank to separate and store stem cells in 1992, today announced results for the fiscal third quarter ended August 31, 2013.

David Portnoy, Cryo-Cell’s Chairman and Co-Chief Executive Officer commented, “Cryo-Cell’s fiscal third quarter 2013 results continue to show that the Company is becoming increasingly more profitable and more successful within the cord blood industry as customers choose Cryo-Cell for its superior quality and top notch service. I know Cryo-Cell has even greater potential that we will strive to realize in the coming years.”

Mark Portnoy, Cryo-Cell’s Co-Chief Executive Officer, added, “The Company’s sales and marketing initiatives have put Cryo-Cell on sounder footing, and we continue to raise the quality of our service in meaningful ways. We believe our qualitative efforts will differentiate us and have a positive impact in the future.”
 
more
Cryo-Cell Reports Second Quarter 2013 Results

OLDSMAR, Fla. – July 15, 2013 Cryo-Cell International, Inc. (OTC:QB Markets Group Symbol: CCEL), the world’s first private cord blood bank to separate and store stem cells in 1992, today announced results for the second quarter ended May 31, 2013. 
 
“I am pleased to report Cryo-Cell’s second quarter results for fiscal year 2013, and in particular, cash flow from operations of almost $600,000, which we believe indicates that Cryo-Cell is growing stronger day by day,” stated David Portnoy, Cryo-Cell’s Chairman and Co-CEO.  “Key metrics of performance such as the 10% increase in revenues, during the second quarter of fiscal 2013 as compared to the second quarter of fiscal 2012 are encouraging.”  Mr. Portnoy continued, “Nonrecurring expenses in the quarter relating to legacy issues included 1.) an additional accrual relating to severance payment to a former executive of $219,000, and 2.) the write-off of approximately $379,000 related to the abandonment of certain previously incurred patent expenses.”
 
Mark Portnoy, Cryo-Cell’s Co-CEO, added, “We are pleased to see the continued improvement in our business results.  The earnings from business operations in the first half of the year demonstrate that our new sales and marketing initiatives have gained traction.”

more
Cryo-Cell Reports First Quarter 2013 Results

OLDSMAR, Fla. – April 5, 2013 – Cryo-Cell International, Inc. (OTC:QB Markets Group Symbol: CCEL) (the “Company”), the world’s first private cord blood bank to separate and store stem cells in 1992, today announced results for the first quarter ended February 28, 2013.  
 
“I am pleased to report Cryo-Cell’s first quarter results, and in particular, cash flow from operations of slightly more than $500,000, which we believe indicates that the Cryo-Cell turnaround is well underway,” stated David Portnoy, Cryo-Cell’s Chairman and Co-CEO.  “Key metrics of performance such as the increase in revenues and the number of specimens processed of 10% and 12%, respectively, during the first quarter of fiscal 2013 as compared to the first quarter of fiscal 2012 are encouraging.”
 
Mark Portnoy, Cryo-Cell’s Co-CEO, added, “It is gratifying to see the progress the Company has made over the last year although we are still dealing with a variety of legacy issues.  With the continued execution of the new sales and marketing initiatives, I expect to see further increases in revenue and earnings.”

more
Cryo-Cell International has the Lowest Beta in the Health Care Services Industry (CCEL, MZEI, AMS, CO, SMED)

Below are the three companies in the Health Care Services industry with the lowest betas. Lower-beta stocks mean minimal volatility and are therefore generally considered to be a less risk and offer more stable returns.

Cryo-Cell International ranks lowest with a a beta of 0.1. Following is Medizone International with a beta of 0.1. American Shared Hospital Services ranks third lowest with a beta of 0.3.

China Cord Blood follows with a beta of 0.4, and Sharps Compliance rounds out the bottom five with a beta of 0.5.

SmarTrend recommended that subscribers consider buying shares of Sharps Compliance on October 17th, 2012 as our technology indicated a new Uptrend was in progress when shares hit $2.90. Since that recommendation, shares of Sharps Compliance have risen 9.2%. We continue to monitor Sharps Compliance for any potential shift so investors can protect gains and will alert SmarTrend subscribers immediately.
more
Cryo-Cell Reports Financial Results and Results of Recent Shareholder Vote

Cryo-Cell International, Inc. (OTC:QB Markets Group Symbol: CCEL), today announced financial results for the second quarter ended May 31, 2012, and the results from the July 10, 2012, Annual Meeting of Shareholders.
more
Key Stakeholders Support Cryo-Cell International Leadership in Proxy Contest

Individuals who are in the best position to observe and evaluate the performance of the current Cryo-Cell International [OTCQB Symbol: CCEL] Board and executive management are strongly supporting them as they face a bid for control of the company by a former Board member. The group assumed leadership in August 2011.
more
Cryo-Cell Leadership Sets the Record Straight on Efforts to Date

Cryo-Cell International, Inc. [OTCQB Symbol: CCEL] updated shareholders with results achieved by the current Board's leadership, which is being challenged for control of the company by previous Board members Ki Yong Choi and his brother-in-law.
more
Cryo-Cell Reports Financial Results For Fiscal 2011

“Cryo-Cell fiscal 2011 results are indicative of a company that is in the process of making many organizational and operational improvements,” stated David Portnoy, Cryo-Cell’s Chairman and Co-CEO. “Although the implementation of these steps is still in the early stages, we are encouraged in our belief that our goals will be achieved.”
more
Cryo-Cell Reports Financial Results For Fiscal 2011

“Cryo-Cell fiscal 2011 results are indicative of a company that is in the process of making many organizational and operational improvements,” stated David Portnoy, Cryo-Cell’s Chairman and Co-CEO. “Although the implementation of these steps is still in the early stages, we are encouraged in our belief that our goals will be achieved.”
more